Flatiron Health has published the Validation of Accuracy for LLM/ML-Extracted Information and Data (VALID) Framework in the Journal of Clinical Oncology Clinical Cancer Informatics. The framework represents the first peer-reviewed approach to evaluating real-world oncology data extracted by large language models and machine learning. The VALID Framework employs three pillars: variable-level performance metrics benchmarking LLM extraction against human abstraction, automated verification checks identifying data inconsistencies, and replication analyses confirming LLM-extracted results match established clinical findings. Flatiron applies this framework to datasets with longitudinal records across millions of patients and over 1.5 billion data points. The framework aims to establish industry standards for AI-extracted clinical data quality whilst maintaining rigour for high-stakes cancer care and drug development decisions.

Abbott Laboratories has integrated its Precision Oncology portfolio into Flatiron Health's OncoEMR platform, giving over 1,600 community cancer centres and 4,700 providers direct access to tests including Oncotype DX and OncoExTra within their clinical workflows. The integration allows clinicians to order and receive cancer diagnostic results without leaving their electronic medical records system. This follows Abbott's recent integration of its Libre continuous glucose monitoring data into Epic's health record system, part of a broader strategy to embed its products into clinical workflows. Whilst the move may enhance test adoption and streamline administrative tasks, analysts suggest it is unlikely to significantly shift Abbott's near-term investment narrative, which remains centred on its core devices business and managing margin pressure from tariffs and foreign exchange headwinds.

Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR(R) platform. * 1 hr ago PR Newswire ABBOTT PARK, Ill. and NEW YORK, March 30, 2026 * Broadens access to Abbott's Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron's North America network, helping accelerate informed treatment decisions * Allows oncologists to order tests and view results directly in the clinical workflow ABBOTT PARK, Ill. and NEW YORK, March 30, 2026 /PRNewswire/ - Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, today announced the integration of Abbott's comprehensive Precision Oncology portfolio into OncoEMR(R), Flatiron's cloud-based Electronic Medical Record (EMR) platform. Through this integration, oncology providers can now digitally order Abbott tests - individually or in combination - and receive status updates and results directly within their existing OncoEMR clinical workflow. Available Abbott tests include the Oncotype DX Breast Recurrence Score(R), OncoExTra(R), Oncodetect(R), and Riskguard(R) tests, enabling clinicians to access the comprehensive portfolio through a single, unified experience. This approach supports more informed treatment decisions across multiple stages of cancer care while helping reduce administrative burden and keeping the focus on patient care. The integration expands access to Abbott's Precision Oncology tests across Flatiron's national network of more than 1,600 community cancer care centers, where 4,700 providers deliver care and where most cancer care in the U.S. takes place. "We're focused on making it easier for clinicians to access the right information at the right moment of care," said Quincy Weatherspoon, VP and GM of Point of Care Solutions, Flatiron Health. "By integrating Abbott's Precision Oncology portfolio directly into OncoEMR, we're reducing friction in the workflow and helping providers move faster - from test ordering to treatment decisions. This is what it looks like to bring more connected, data-driven care to the point of care." "For community oncology practices, where most cancer care is delivered, this removes a key barrier to accessing our portfolio at the point of care, helping accelerate treatment decisions and enabling more informed, personalized patient care," said Brian Baranick, vice president, Precision Oncology, Abbott. About Abbott Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Its 122,000 colleagues serve people in more than 160 countries. Connect with Mycarrollcountynews at abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. About Flatiron Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, Mycarrollcountynews continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. SOURCE Abbott